Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review

Hodgkin lymphoma (HL) is a potentially curable lymphoma, and modern therapy is expected to successfully cure more than 80% of the patients. Second-line salvage high-dose chemotherapy and autologous stem cell transplantation (auto-SCT) have an established role in the management of refractory and rela...

Full description

Saved in:
Bibliographic Details
Published in:Journal of immunology research 2015-01, Vol.2015 (2015), p.1-11
Main Authors: Gentile, Massimo, Irrera, Giuseppe, Recchia, Anna Grazia, Martino, Massimo, Fedele, Roberta, Morabito, Fortunato
Format: Article
Language:English
Subjects:
Animals
Antibodies, Monoclonal - therapeutic use
Bone marrow
Cell Cycle - drug effects
Chemotherapy
Drug dosages
Drug Resistance, Neoplasm
Hematology
Hodgkin Disease - therapy
Humans
Immunology
Ki-1 Antigen - immunology
Leukemia
Lymphoma
Medical prognosis
Molecular Targeted Therapy
Mortality
Protein Kinase Inhibitors - therapeutic use
Recurrence
Review
Signal Transduction - drug effects
Stem Cell Transplantation
Stem cells
Transplants & implants
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hodgkin lymphoma (HL) is a potentially curable lymphoma, and modern therapy is expected to successfully cure more than 80% of the patients. Second-line salvage high-dose chemotherapy and autologous stem cell transplantation (auto-SCT) have an established role in the management of refractory and relapsed HL, leading to long-lasting responses in approximately 50% of relapsed patients and a minority of refractory patients. Patients progressing after intensive treatments, such as auto-SCT, have a very poor outcome. Allogeneic SCT represents the only strategy with a curative potential for these patients; however, its role is controversial. Based on recent knowledge of HL pathology, biology, and immunology, antibody-drug conjugates targeting CD30, small molecule inhibitors of cell signaling, and antibodies that inhibit immune checkpoints are currently explored. This review will discuss the clinical results regarding auto-SCT and allo-SCT as well as the current role of emerging new treatment strategies.
ISSN:2314-8861
2314-7156
DOI:10.1155/2015/968212